摘要
目的:探讨氟伏沙明治疗伴有焦虑症状的抑郁症的疗效与安全性。方法:将69例难治性抑郁症同时伴有焦虑症状的患者分为氟伏沙明组35例,马普替林组34例。观察8周,于治疗前和治疗后1、2、4及8周末采用汉密尔顿抑郁量表(HAMD-17)及汉密顿焦虑量表(HAMA)评定疗效。用副反应量表(TFSS)评定不良反应。结果:氟伏沙明组显效率为78%,马普替林组显效率为75%。氟伏沙明组不良反应相对较少。结论:氟伏沙明治疗伴发焦虑症状的抑郁症疗效较好,且起效快,不良反应少。
Objective：To investigate the efficacy and safety of fluvoxamine in the treatment of patients with refractory depression and anxiety.Methods：A total of patients with refractory depression and anxiety were randomly assigned to 8 weeks treatment with fluvoxamine（n=35） or maprotiline（n=34） and changes from baseline in the Hamilton Rating Scale for Depression（HAMD-17）,total scores of two groups,and Treatment Emergent Symptom Scale（TESS） were compared at 1 week before treatment and 1,2,4,8 weeks after treatment.Results：The significant efficacy rates of Fluvoxamine group was 78%,while that was 75% in the maprotiline group.There were less side effects in the Fluvoxamine group than the other group.Conclusion：Fluvoxamine is better thanmaprotilinein the treatment of refractory depression and anxiety,it shows better efficacy and less side effects.It is beneficial to improve the trerapeutic compliance of depressive patients.
出处
《中国当代医药》
2010年第6期48-49,共2页
China Modern Medicine
关键词
抑郁
焦虑
疗效
氟伏沙明
马普替林
Depression
Anxiety
Efficacy
Fluvoxamine
Maprotiline
